基于皮拉的小分子激酶抑制剂:临床应用和专利审查 (2019-2023)
1Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, 11671, Saudi Arabia.
Future medicinal chemistry
|August 27, 2024
概括
基于皮拉的小分子激酶抑制剂在治疗癌症和自身免疫性疾病方面表现有前途. 这些口服活性药物具有良好的临床活性,可控毒性,推进治疗选择.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 蛋白激酶在细胞信号传递中至关重要,使其成为癌症和自身免疫性疾病等疾病的治疗点.
- 小分子激酶抑制剂,特别是那些具有异环,含的支架,如pyrazine,正在积极开发.
- 基于pyrazine的抑制剂在各种条件下已经证明了临床疗效和可控的毒性.
研究的目的:
- 审查最近 (2019-2023) 的基于pyrazine的小分子激酶抑制剂.
- 总结FDA批准的药物,专利化合物及其临床前/临床数据.
- 提供针对性激酶,支架,效能,选择性和生物结果的见解.
主要方法:
- 在科学数据库和专利库的文献中搜索基于pyrazine的激酶抑制剂.
- 对针对性激酶,化学结构和体外/体内研究结果的已公布数据的分析.
- 收集关于临床试验结果的信息,包括疗效和毒性概况.
主要成果:
- 已经确定了几种基于pyrazine的强效和选择性激酶抑制剂,并已进入临床试验.
- 这些抑制剂在恶性瘤和免疫疾病中表现出良好的临床活性和可控的毒性.
- 所有审查的基于pyrazine的激酶抑制剂都是口服活性,提高了患者的服药性.
结论:
- 基于皮拉的小分子代表了具有治疗潜力的重要类别的激酶抑制剂.
- 目前正在进行的开发和临床应用强调了它们在治疗癌症和免疫相关疾病方面的重要性.
- 进一步的研究和开发是有必要的,以优化这些药物用于更广泛的临床应用.
相关概念视频
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drug Discovery: Overview
7.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.7K


